35166-33-7

Usage

Chemical Properties

Colorless to light yellow liquid

InChI:InChI=1/C5H7NO2/c1-4-2-5(3-7)6-8-4/h2,7H,3H2,1H3

Upstream product

• 3511-32-8 5-methyl-3(2H)-furanone 
• 3209-72-1 ethyl 5-methylisoxazole-3-carboxylate 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 19788-35-3 methyl 5-methylisoxazole-3-carboxylate 
• 3405-77-4 5-methylisoxazole 3-carboxylic acid 

Downstream Products

• 62254-74-4 5-methyl-isoxazole-3-carbaldehyde 
• 3405-77-4 5-methylisoxazole 3-carboxylic acid 
• 60148-49-4 (5-ethylisoxazol-3-yl)methanol 
• 84654-36-4 (5-Methylsulfanylmethyl-isoxazol-3-yl)-methanol 
• 130628-75-0 3-(bromomethyl)-5-methylisoxazole 
• 783325-24-6 methanesulfonic acid 5-methyl-isoxazol-3-ylmethyl ester 
• 156787-21-2 <<3-<5-<3-<2,6-dimethyl-4-<3-(5-methyl-1,2,4-oxaadiazolyl)>phenoxy>propyl>isoxazolyl>>methoxy>dimethyl(dimethylethyl)silane 
• 154016-48-5 (5-methyl-3-isoxazolyl)methylamine 
• 154016-53-2 3-(azidomethyl)-5-methylisoxazole 
• 107355-85-1 5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-(hydroxymethyl)isoxazole 
• 107355-90-8 2-<<<5-<5-<2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy>pentyl>-3-isoxazolyl>methoxy>methoxy>ethanol 
• 107355-89-5 Acetic acid 2-(5-{5-[2,6-dichloro-4-(4,5-dihydro-oxazol-2-yl)-phenoxy]-pentyl}-isoxazol-3-ylmethoxymethoxy)-ethyl ester 
• 262439-98-5 (5-methyl-3-isoxazolyl)methyl N-[4-(4-amino-7-tetrahydro-2H-4-pyranyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]carbamate 
• 872180-94-4 C₁₂H₉FN₂O₂ 

Relevant academic research and scientific papers

NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM

The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

Modeling linear and cyclic PKS intermediates through atom replacement

The mechanistic details of many polyketide synthases (PKSs) remain elusive due to the instability of transient intermediates that are not accessible via conventional methods. Here we report an atom replacement strategy that enables the rapid preparation o

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

HETEROARYL COMPOUNDS AS PDE10A INHIBITORS

The present invention provides heteroaryl compounds as Phosphodiesterase 10A (PDE I OA) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 10A enzyme. Also provided herein are processes for preparing compounds described herein, Formula (I), intermediates used in their synthesis, pharmaceutical compositions thereof.

Substituted enaminones, their derivatives and uses thereof

The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine a

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR

A compound of formula (I) : (wherein R1-R10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X1 is -O-, -S-, -NR11- (wherein R11 is hydrogen, lower alkyl or the like), -CR12R13CO-, -(CR12R13)mO-, -O(CR12R13)m- (wherein R12 and R13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3) or the like, X2 is a bond, -O-, -S-, -NR14- (wherein R14 is hydrogen, lower alkyl or the like, R14 and R6 can be taken together with the neighboring atom to form a ring) or -CR15R16-(wherein R15 and R16 are each independently hydrogen or lower alkyl, R15 and R6 or R10 can be taken together with the neighboring carbon atom to form a ring, R16 and R9 can be joined together to form a bond), X3 is COOR17, C( = NR17)NR18OR19 or the like), a pharmaceutically acceptable salt or a solvate thereof.

Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives

The present invention is a compound of formula wherein R1 is halogen or lower alkyl; R2 is hydrogen, lower alkyl, cycloalkyl, —(CH2)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH2)m-indolyl; R3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A α5 receptor binding sites.

Process for producing cyclopropanecarboxylates

There is disclosed a process process for producing a cyclopropanecarboxylate of formula (1): 1which process comprises reacting cyclopropanecarboxylic acid of formula (2): 2with a monohydroxy compound of formula (3): R6OH??(3),in the presence of a catalyst compound comprising an element of to Group 4 of the Periodic Table of Elements.

Cleavage of MEM ethers by tetrahalozincate reagents

A modification of the zinc halide-mediated removal of the MEM group is described. By the expedient of adding two molar equivalents of ethereal hydrogen chloride or of lithium halide, the method is extended to substrates which otherwise chelate the zinc reagent without undergoing deprotection. The compatibility of the resulting reagent Systems with other functional groups is demonstrated, and examples are presented where deprotection of mono-MEM-protected 1,2- and 1,3-diols can be carried out, avoiding the cyclisation which occurs normally.